SCHEMBL878759

SCHEMBL878759

CC(C)CNc1ccc(C(O)c2c[nH]c3ncccc23)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.42
HCAR3 P49019 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
CSF1R P07333 1/20 0.39
KIT P10721 1/20 0.39
GRM8 O00222 1/20 0.38
GRM4 Q14833 1/20 0.38
GPR84 Q9NQS5 1/20 0.37
DYRK1A Q13627 5/20 0.37
GSK3B P49841 2/20 0.37
CDK9 P50750 2/20 0.37
CCNT1 O60563 1/20 0.37
MAP2K1 Q02750 1/20 0.36
BRD4 O60885 1/20 0.36
AXL P30530 1/20 0.35
MAPT P10636 1/20 0.35
MTNR1A P48039 1/20 0.35
CYP2D6 P10635 1/20 0.34
PDE10A Q9Y233 1/20 0.34
CDC7 O00311 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267562 0.83 CDC7 (0.41) METCSF1RKITGRM8GRM4
SCHEMBL1268047 0.81 CSF1R (0.50) METCSF1RKITDYRK1AGSK3B
SCHEMBL878749 0.80 CDC7 (0.48) METCSF1RKITGRM4DYRK1A
SCHEMBL22978447 0.80 GRM8 (0.46) METGRM8GRM4GPR84DYRK1A
SCHEMBL878781 0.79 CSF1R (0.68) METCSF1RKITDYRK1AGSK3B
SCHEMBL21872984 0.77 CDC7 (0.41) METGRM8GRM4GPR84DYRK1A
SCHEMBL1267952 0.77 AXL (0.48) METGRM8GRM4GPR84GSK3B
SCHEMBL1267499 0.77 CSF1R (0.64) METHCAR3HCAR2CSF1RKIT
SCHEMBL22988869 0.76 MAP2K1 (0.40) METGRM8GRM4DYRK1AGSK3B
SCHEMBL858185 0.75 HCAR3 (0.54) HCAR3HCAR2CSF1RKITGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 US disclosed
US-9550768-B2 Kinase modulation and indications therefor PLEXXIKON INC. (US) 2017-01-24 US disclosed
US-9487515-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2016-11-08 US disclosed
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2016-06-23 US disclosed
US-9169250-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2015-10-27 US disclosed
US-20150290205-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2015-10-15 US disclosed
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2015-09-24 US disclosed
EP-1696920-B1 COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS PLEXXIKON INC (US) 2014-10-29 EP disclosed
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2014-08-28 US disclosed
US-7504509-B2 Compounds and methods for development of Ret modulators PLEXXIKON, INC. (US) 2009-03-17 US disclosed
CN-101223169-A Pyrrolo [2, 3-b ] pyridine derivative protein kinase inhibitors PLEXXIKON INC (US) 2008-07-16 CN disclosed
WO-2008064265-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO disclosed
EP-1885723-A2 PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2008-02-13 EP disclosed
US-20070066641-A1 Compounds and methods for development of RET modulators PLEXXIKON, INC. 2007-03-22 US disclosed
US-20070066641-A1 Compounds and methods for development of RET modulators PLEXXIKON, INC. 2007-03-22 US disclosed
US-20070049615-A1 Compounds and methods for development of Ret modulators PLEXXIKON, INC. 2007-03-01 US disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed
WO-2007013896-A2 PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-02-01 WO disclosed
WO-2007002433-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 MET 68/4885HCAR3 588/4885HCAR2 292/4885
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 MET 68/4885HCAR3 588/4885HCAR2 292/4885
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 MET 556/4885HCAR3 3320/4885HCAR2 3241/4885
US-20150290205-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 MET 556/4885HCAR3 3320/4885HCAR2 3241/4885
US-20070066641-A1 Compounds and methods for development of RET modulators RET, FGFR1, FGFR3 MET 18/4885HCAR3 440/4885HCAR2 841/4885
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 MET 556/4885HCAR3 3320/4885HCAR2 3241/4885
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 MET 68/4885HCAR3 588/4885HCAR2 292/4885
US-20070049615-A1 Compounds and methods for development of Ret modulators RET, GFRA1, GFRA3 MET 40/4885HCAR3 994/4885HCAR2 1423/4885
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor KIT, FLT3, FLT1 MET 64/4885HCAR3 906/4885HCAR2 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.